Literature DB >> 15067080

A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release.

Andreas Elssner1, Michelle Duncan, Mikhail Gavrilin, Mark D Wewers.   

Abstract

The release of IL-1 beta is a tightly controlled process that requires induced synthesis of the precursor pro-IL-1 beta and a second stimulus that initiates cleavage and secretion of mature IL-1 beta. Although ATP as a second stimulus potently promotes IL-1 beta maturation and release via P2X(7) receptor activation, millimolar ATP concentrations are needed. The human cathelicidin-derived peptide LL37 is a potent antimicrobial peptide produced predominantly by neutrophils and epithelial cells. In this study, we report that LL37 stimulation of LPS-primed monocytes leads to maturation and release of IL-1 beta via the P2X(7) receptor. LL37 induces a transient release of ATP, membrane permeability, caspase-1 activation, and IL-1 beta release without cell cytotoxicity. IL-1 beta release and cell permeability are suppressed by pretreatment with the P2X(7) inhibitors oxidized ATP, KN04, and KN62. In the presence of apyrase, which hydrolyzes ATP to AMP, the effect of LL37 was not altered, indicating that LL37 rather than autocrine ATP is responsible for the activation of the P2X(7) receptor. We conclude that endogenous LL37 may promote IL-1 beta processing and release via direct activation of P2X(7) receptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15067080     DOI: 10.4049/jimmunol.172.8.4987

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  157 in total

Review 1.  A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases.

Authors:  Nishkantha Arulkumaran; Robert J Unwin; Frederick Wk Tam
Journal:  Expert Opin Investig Drugs       Date:  2011-04-21       Impact factor: 6.206

2.  Signaling pathways mediating chemokine induction in keratinocytes by cathelicidin LL-37 and flagellin.

Authors:  Anastasia Nijnik; Jelena Pistolic; Niall C J Filewod; Robert E W Hancock
Journal:  J Innate Immun       Date:  2012-04-17       Impact factor: 7.349

3.  Cathelicidin peptide LL-37 modulates TREM-1 expression and inflammatory responses to microbial compounds.

Authors:  Gimano D Amatngalim; Anastasia Nijnik; Pieter S Hiemstra; Robert E W Hancock
Journal:  Inflammation       Date:  2011-10       Impact factor: 4.092

4.  Cathelicidin LL-37 peptide regulates endothelial cell stiffness and endothelial barrier permeability.

Authors:  Fitzroy J Byfield; Qi Wen; Katarzyna Leszczynska; Alina Kulakowska; Zbigniew Namiot; Paul A Janmey; Robert Bucki
Journal:  Am J Physiol Cell Physiol       Date:  2010-10-13       Impact factor: 4.249

Review 5.  Intestinal mucosal responses to microbial infection.

Authors:  Lars Eckmann; Martin F Kagnoff
Journal:  Springer Semin Immunopathol       Date:  2005-06-01

6.  Apoptosis of airway epithelial cells: human serum sensitive induction by the cathelicidin LL-37.

Authors:  Y Elaine Lau; Dawn M E Bowdish; Celine Cosseau; Robert E W Hancock; Donald J Davidson
Journal:  Am J Respir Cell Mol Biol       Date:  2005-12-09       Impact factor: 6.914

7.  Defensins and other antimicrobial peptides at the ocular surface.

Authors:  Alison M McDermott
Journal:  Ocul Surf       Date:  2004-10       Impact factor: 5.033

8.  The neutrophil antimicrobial peptide cathelicidin promotes Th17 differentiation.

Authors:  Danielle Minns; Katie J Smith; Virginia Alessandrini; Gareth Hardisty; Lauren Melrose; Lucy Jackson-Jones; Andrew S MacDonald; Donald J Davidson; Emily Gwyer Findlay
Journal:  Nat Commun       Date:  2021-02-24       Impact factor: 14.919

Review 9.  Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states.

Authors:  D L Donnelly-Roberts; M F Jarvis
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

10.  Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13.

Authors:  Robert Bucki; Dorota B Namiot; Zbigniew Namiot; Paul B Savage; Paul A Janmey
Journal:  J Antimicrob Chemother       Date:  2008-05-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.